Key result
Elevated CHA2DS2-VASc score linked to ~86% higher odds of no-reflow after PCI.
Why the study?
No-reflow is a serious complication of PCI linked to adverse outcomes, but the predictive value of the CHA2DS2-VASc score for no-reflow remains uncertain.
Is the CHA2DS2-VASc score associated with the occurrence of no-reflow phenomenon in patients undergoing percutaneous coronary intervention?
Meta-Analysis (n=6,557)
Yes
Is the CHA2DS2-VASc score associated with the occurrence of no-reflow phenomenon in patients undergoing percutaneous coronary intervention?
Effect estimate: OR 1.86 (95% CI 1.51–2.29)
Absolute Event Rate: 16.3% vs 83.7%
p-value: p=<0.00001
This systematic review and meta-analysis aims to evaluate the predictive value of the CHA2DS2-VASc score for the no-reflow phenomenon after percutaneous coronary intervention.
Warrants caution for no-reflow in high CHA2DS2-VASc PCI patients; extends score utility beyond thromboembolic risk.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Özbay et al. (2026) conducted a meta-analysis in Patients undergoing percutaneous coronary intervention (PCI), including those with acute ST-segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction (NSTEMI), and saphenous vein graft intervention (n=6,557). Elevated CHA2DS2-VASc score vs. Lower CHA2DS2-VASc score was evaluated on Occurrence of no-reflow (NR) phenomenon after PCI (OR 1.86, 95% CI 1.51–2.29, p=<0.00001). An elevated CHA2DS2-VASc score was associated with an 86% higher odds of no-reflow phenomenon after PCI (OR 1.86; 95% CI 1.51–2.29; p < 0.00001) in 6,557 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: